Freenome (FRNM) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
29 Aug, 2026Executive summary
Blank check company focused on completing a business combination, with no operating revenues to date and activities limited to formation, IPO, and identifying a target for merger or acquisition.
Entered into a Business Combination Agreement with Freenome Holdings, Inc., expected to close in the first half of 2026, subject to shareholder and regulatory approvals.
Filed a proxy statement to extend the deadline for consummating a business combination from June 13, 2026 to June 13, 2027.
Financial highlights
Net loss of $51,749 for the three months ended March 31, 2026, compared to net income of $678,555 for the same period in 2025.
Interest income from investments in the Trust Account was $841,181 for Q1 2026, down from $961,912 in Q1 2025.
General and administrative expenses increased to $858,834 in Q1 2026 from $255,958 in Q1 2025.
Cash and investments held in Trust Account totaled $92,679,503 as of March 31, 2026.
Cash used in operating activities was $297,852 for Q1 2026.
Outlook and guidance
The company does not expect to generate operating revenues until after the completion of its initial business combination.
Management plans to complete the Freenome transaction before the mandatory liquidation date, but substantial doubt exists about the ability to continue as a going concern if no combination is completed.
If the extension proposal is not approved and no business combination is completed by June 13, 2026, the company will liquidate.
Latest events from Freenome
- IPO filing details a well-funded, AI-driven cancer screening innovator with FDA approval and major partnerships.FRNM
Registration filing - SPAC raised $86.25M, reports $1.91M net income, must acquire or liquidate in 24 months.FRNM
Q4 2024 - SPAC holds $91.9M in trust, targets Freenome merger in 2026, but faces going concern risks.FRNM
Q4 2025 - Vote sought to extend business combination deadline by one year, with redemption rights offered.FRNM
Proxy filing - Q1 2025 net income reached $678,555, with $90.6M in assets and ongoing exposure to global market risks.FRNM
Q1 2025 - Q2 2025 net income reached $754,847, with ongoing risks tied to business combination completion.FRNM
Q2 2025 - Vote sought to extend merger deadline by one year; redemption rights and board support highlighted.FRNM
Proxy filing - Q3 net income reached $981,482, with all proceeds held in trust pending a business combination.FRNM
Q3 2024 - IPO completed, $86.25M raised; Q2 net income $102,875; business combination targeted by June 2026.FRNM
Q2 2024